News Archive

Since the launch of the BioPark Initiative in 2003, the BioPark has grown to include nearly three dozen companies with more than 1,000 employees. Looking out a fifth-floor window of BioPark Building One, BioPark Senior Vice President Jane Shaab pointed out other BioPark facilities, such as the Maryland Proton Treatment Center, the Maryland Forensic Medical Center, the newly added Lion Brothers Building, and the construction site where work has begun on BioPark Building Three, a facility that will double the number of BioPark employees.

The Food and Drug Administration on Wednesday approved the second in a radically new class of treatments that genetically reboot a patient’s own immune cells to kill cancer.

Inova Health System is bringing Northern Virginia tech investor Rick Gordon into the fold.

This is the latest in my “superstar effect” series. Richard Florida posted an interesting analysis of venture capital investments over at City Lab.

Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.

Germantown-based bioengineering company Intrexon Corp. will have access to up to $100 million of new capital through a deal with an affiliate company controlled by its founder and chairman, Randal “RJ” Kirk.

The operating partner for 1313 Innovation’s co-working space in Wilmington is merging with a Washington, DC organization.

1313 operates from the Hercules Plaza building in downtown Wilmington, with Benjamin’s desk serving as its partner.

Illumina Ventures, a San Francisco-based early-stage venture capital firm, closed its maiden fund, at $230m.

Launched with an initial $100m investment from Illumina, Illumina Ventures has then been supported by a mix of corporate, institutional, sovereign, and individual investors.

VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines announced today the receipt of a Phase I grant from the National Cancer Institute under auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The $298,729 grant under the Award Number R43CA217445 is focused on “the development of a novel Virus-Like Particle vaccine-based cancer immunotherapy targeting PD-L1” and will also explore broader immune checkpoint inhibition mechanisms.